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ABSTRACT 27 
The hypervariable region-1 (HVR1) (amino acids (aa) 384-410) on the E2 glycoprotein of 28 
hepatitis C virus contributes to persistent infection by evolving escape mutations that attenuate 29 
binding of inhibitory antibodies and by blocking access of broadly neutralizing antibodies to 30 
their epitopes. A third proposed mechanism of immune antagonism is that poorly neutralizing 31 
antibodies binding to HVR1 interfere with binding of other superior neutralizing antibodies. 32 
Epitope mapping of human monoclonal antibodies (HMAbs) that bind to an adjacent, 33 
conserved domain on E2 encompassing aa 412-423 revealed two subsets, designated as HC33 34 
HMAbs. While both subsets have contact residues within aa 412-423, alanine scanning 35 
mutagenesis suggested that one subset, which includes HC33.8, has an additional contact 36 
residue within HVR1. To test for interference of anti-HVR1 antibodies with binding of antibodies 37 
to aa 412-423 and other E2 determinants recognized by broadly neutralizing HMAbs, two 38 
murine MAbs against HVR1 (H77.16) and aa 412-423 (H77.39) were studied. As expected, 39 
H77.39 inhibited the binding of all HC33 HMAbs. Unexpectedly, H77.16 also inhibited the 40 
binding of both subsets of HC33 HMAbs. This inhibition also was observed against other broadly 41 
neutralizing HMAbs to epitopes outside of aa 412-423. Combination antibody neutralization 42 
studies by the median-effect analysis method with H77.16 and broadly reactive HMAbs 43 
revealed antagonism between these antibodies. Structural studies demonstrated 44 
conformational flexibility in this antigenic region, which supports the possibility of anti-HVR1 45 
antibodies hindering the binding of broadly neutralizing MAbs. These findings support the 46 
hypothesis that anti-HVR1 antibodies can interfere with a protective humoral response against 47 
HCV infection.    48 
 Importance. The HVR1 contributes to persistent infection by evolving mutations that 49 
escape from neutralizing antibodies to HVR1 and by shielding broadly neutralizing antibodies 50 
from their epitopes. This study provides insight into a new immune antagonism mechanism by 51 
which the binding of antibodies to HVR1 blocks the binding and activity of broadly neutralizing 52 
antibodies to HCV. Immunization strategies that avoid the induction of HVR1 antibodies should 53 
increase the inhibitory activity of broadly neutralizing anti-HCV antibodies elicited by candidate 54 
vaccines. 55 
 56 
  57 
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INTRODUCTION 58 
Up to 170 million people worldwide are infected with hepatitis C virus (HCV) with significant 59 
risk for liver failure and hepatocellular carcinoma. The World Health Organization estimates an 60 
annual increase in the global burden by two million new infections (40) and in the United States 61 
HCV is increasing in young adults from injection drug use (25). Multiple lines of evidence 62 
suggest that CD4+ and CD8+ T cell responses are needed to control acute infection but 63 
insufficient to prevent long-term persistence (2). Accumulating data indicate that neutralizing 64 
antibodies are an important correlate of HCV clearance. In chimpanzee studies, an infectious 65 
inoculum obtained during acute infection from a patient who eventually developed chronic 66 
HCV hepatitis could be neutralized by in vitro incubation with plasma of the same subject 67 
collected at 2 years after the initial infection (12). A neutralizing antibody response measured 68 
against pseudotyped retroviral particles expressing HCV E1E2 glycoproteins (HCVpp) has been 69 
associated with control of infection in single source outbreaks of acute HCV infections (35). In 70 
addition, antibodies to HCV E2 prevent (28, 32) and clear established infection (8) in a human 71 
liver-mouse chimeric model. In spite of the relationship between antibodies and protection 72 
against HCV infection, 104-106 virions per milliliter of serum can be detected during chronic 73 
infection even in the presence of high levels of neutralizing antibodies in serum.  74 
One driver of persistent viremia is a high degree of viral variants or “quasispecies”. From a viral 75 
replication rate of 1012 copies per day with an error prone NS5B RNA-dependent polymerase, 76 
the estimated mutation rate is 2.0X10-3 base substitutions per genome per year (4). A major 77 
determinant of antibody-mediated neutralization is the first 27 amino acids (aa 384-410), the 78 
hypervariable region 1 (HVR1), located at the N-terminus of HCV E2 (41). This E2 segment is 79 
highly immunogenic, and antibodies against HVR1 can be detected in the majority of HCV 80 
infected individuals (51). However, antibodies to HVR1 over time select for viral variants that 81 
escape the existing antibody response (47). The limited nature of the B cell response to this 82 
region is shown in studies of HCV evolution from acute to chronic disease (10, 46). Sequential 83 
autologous serum antibodies inefficiently neutralize emerging variants, in contrast to their 84 
capacity to neutralize earlier quasispecies. Viral escape is associated with mutations within 85 
HVR1. Other negative modulators of antibody-mediated neutralization include cell-to-cell 86 
transmission, virion-associated lipoproteins, virus envelope protein-associated glycans, and the 87 
HVR1 itself; the latter can mask epitopes or limit access of virus neutralizing antibodies to their 88 
epitopes (14, 43, 44). Indeed, virions lacking HVR1 are less susceptible to neutralization by anti-89 
SR-B1 antibodies, but are more sensitive to antibody- and soluble CD81-mediated 90 
neutralization (1, 37). It has been suggested that HVR1 partly shields CD81 binding sites and 91 
conserved epitopes mediating virus neutralization (1).  92 
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The concept of interfering antibodies is controversial but remains a possible mechanism that 93 
contributes to the development of persistent HCV infection in infected subjects (17, 42, 49, 50). 94 
In this report, we performed more extensive epitope mapping of a panel of HMAbs to a highly 95 
conserved region on the E2 glycoprotein encompassing aa 412-423, designated as HC33-related 96 
antibodies (17). Mapping by binding against a library of alanine substitution E2 mutants from aa 97 
384 to aa 446 revealed two subsets of HC33 HMAbs. Although both subsets have contact 98 
residues within aa 412-423, one subset included a contact residue within HVR1. This raised the 99 
possibility of anti-HVR1 antibodies interfere with the neutralizing activities of antibodies to aa 100 
412-423. Two murine MAbs were utilized to explore the relationship between anti-HVR1 and 101 
antibodies against aa 412-423. Surprisingly, the anti-HVR1 antibody inhibited the binding and 102 
neutralization of both sets of HC33 HMAbs. This interference of binding and neutralization also 103 
was observed against other broadly neutralizing HCV HMAbs that have contact residues outside 104 
of aa 412-423. Thus, immunization strategies that avoid the induction of HVR1 antibodies 105 
should increase the inhibitory activity of broadly neutralizing anti-HCV antibodies. 106 
  107 
 108 
MATERIALS AND METHODS 109 
Cells, viruses and antibodies. HEK-293T cells were obtained from the ATCC. Huh7.5 cells 110 
(generously provided by Dr. C. Rice, Rockefeller University) were grown in Dulbecco's modified 111 
minimal essential medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal calf serum 112 
(Sigma-Aldrich Co., St. Louis, MO) and 2 mM glutamine. The genotype 1a HJ3-5 recombinant 113 
HCVcc was generously provided by Dr. Stanley Lemon (University of North Carolina at Chapel 114 
Hill) (48). HMAbs CBH-7, HC-1, HC-11, HC84.20, HC84.20, HC-84.26, HC33.1, HC33.4, HC33.8 115 
and HC33.29 against HCV E2 glycoprotein were produced as described (13, 17, 22-24). Mouse 116 
MAbs H77.16 and H77.39 and their Fab fragments against HCV E2 glycoprotein were produced 117 
as described (38).   118 
 119 
Binding to E2 glycoprotein. A standard ELISA was used (24) to compare HMAb binding to wt 120 
and ΔHVR1 HCV E2 glycoproteins. In some experiments, incubations were performed at 121 
different temperature or in different sequence when paired with H77.16. Briefly, ELISA plates 122 
were coated with Galanthus nivalis lectin (GNA) and blocked with 2.5% non-fat dry milk and 123 
2.5% normal goat serum in PBS supplemented with 0.1% Tween 20. Lysates of cells expressing 124 
HCV E2 glycoproteins were captured by GNA onto the microtiter plate, followed by incubation 125 
with HMAbs and then washing. Bound HMAb was detected by incubation with alkaline 126 
phosphatase-conjugated goat-anti-human IgG (Promega; Madison, WI), followed by incubation 127 
with p-nitrophenyl phosphate (Sigma) for color development. Absorbance was measured at 128 
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405/570 nm. The assay was carried out in triplicate in three independent assays for each 129 
HMAb.   130 
 131 
Inhibition assay. An ELISA measured the inhibition by mouse MAbs of HMAb binding to GNA-132 
captured E2 glycoproteins (20). Briefly, microtiter plates were coated with GNA and blocked 133 
with 2.5% BSA and 2.5% normal goat serum in 0.1% Tween-PBS. Pre-titrated mouse MAb was 134 
added to each well at a saturating concentration. After 1 h, HMAb was added at a 135 
concentration corresponding to 65%-75% of the maximal OD level, incubated for 30 min at 136 
either room temperature or at 400C and then washed. Bound HMAb was detected as described 137 
above. This assay was carried out in triplicate a minimum of two times for each HMAb.   138 
 139 
Epitope mapping. Epitope mapping was performed using alanine substitution mutants of a 140 
defined E2 region (aa 404-425) by ELISA. Alanine substitution mutants were constructed in 141 
plasmids carrying the 1a H77C E1E2 coding sequence (GenBank accession nos. AF009606), as 142 
previously described (21). All mutations were confirmed by DNA sequence analysis (Elim 143 
Biopharmaceuticals, Inc. Hayward, CA) for the desired mutation and for exclusion of 144 
unexpected residue changes in the full-length E1-E2 encoding sequence. The resulting plasmids 145 
were transfected into HEK293T cells for transient protein expression using the calcium-146 
phosphate method, as suggested by the manufacturer (Clontech, Mountain View, CA).  147 
Antibody cooperativity for virus neutralization. Synergistic, additive or antagonistic 148 
cooperativity by two antibodies for virus neutralization was evaluated by the median-effect 149 
analysis method, as described (5, 6) using the CompuSyn software (ComboSyn Inc, Paramus, 150 
New Jersey). The approach takes into account the potency, the shape and the slope of the 151 
dose-dependent neutralization curve of each antibody alone and in combination, at a constant 152 
ratio, to calculate a CI. A CI value of 1 indicates additive effect, <1 indicates synergism and >1 153 
indicates antagonism. For each antibody, dose-dependent neutralization was measured initially 154 
to determine the concentration that resulted in 50% reduction (IC50 value). The constant ratio 155 
of the combined antibodies was set by the IC50 values of the two antibodies. Neutralization of a 156 
serial two-fold dilution of each antibody and in combination was then measured in a range of 157 
concentrations above and below the IC50 values. The measured neutralization values were 158 
entered in the program as fractional effect (FA) in the range 0.01<FA<0.99 for each of the two 159 
antibodies and in combination. The software determines the linear correlation coefficient, r, of 160 
each curve to indicate the fit or conformity of the data with respect to the median-effect 161 
method and calculates the CI values in relation to FA values. The 1a HCVcc and each HMAb or 162 
combination of HMAbs were incubated for 1 h at 37°C and then plated onto Huh7.5 cell 163 
monolayers (3.2 x 104 cells∕well) that were grown in 8-well chamber slides (Nalge Nunc, 164 
 6
Rochester, NY) for virus neutralization assay as described previously (17). These assays were 165 
carried out in four replicates for each HMAb and combination of HMAbs.   166 
Production and purification of recombinant Fab molecules HC33.4 and HC33.8. Synthetic 167 
genes that were codon optimized for Drosophila melanogaster encoding for heavy and light 168 
chains of the Fab regions of each antibody were cloned into a Drosophila S2 Fab expression 169 
vector containing a double Strep tag for efficient affinity purification. Drosophila S2 cells were 170 
transfected with these plasmids as reported previously (15). For large-scale production, cells 171 
were induced with 5 μM CdCl2 at a density of approximately 107 cells/ml for 7 days, pelleted 172 
and Fabs were purified by affinity chromatography from the supernatant using a Strep Tactin 173 
Superflow column followed by size exclusion chromatography using a Superdex 200 column. 174 
Purified monomeric Fab was concentrated to approximately 25 mg/ml. 175 
Complex formation, crystallization, data collection, structure determination and refinement. 176 
A synthetic peptide comprising residues 406-425 (PGAKQNIQLINTNGSWHINST) of the H77 177 
strain was synthetized by GenScript (> 98% purity) and dissolved in water at 10 mg/ml. Fab-178 
peptide complexes were formed overnight at 277oK containing 12 mg/ml Fab + 2 mg/ml 179 
peptide. HC33.4-peptide complex crystals were grown at 293oK using the hanging-drop vapor-180 
diffusion method in drops containing 1 μl complex solution (14 mg/ml in 10 mM Tris pH 8.0, 181 
150 mM NaCl) mixed with 1 μl reservoir solution containing 100 mM sodium citrate pH 5.2, 300 182 
mM ammonium sulfate, 100 mM potassium phosphate and 1 M lithium chloride. Diffraction 183 
quality crystals of the HC33.8/peptide complex were grown at 293oK as described above using a 184 
seed stock derived from HC33.4/peptide complex crystals and reservoir solution containing 32% 185 
PEG 4000, 100 mM Tris-HCl pH 8.5 and 800 mM lithium chloride with 0.5 μl of seed stock 186 
solution. Rock-like crystals appeared after one week and were flash-frozen in mother liquor 187 
with 20% glycerol. Spacegroups and cell dimensions refinement statistics are summarized in 188 
Table 1. Data were collected at the Synchrotron Soleil (Proxima 1) for the HC33.4 complex 189 
crystals and at the SLS (PX 1) for the HC33.8 complex crystals. Data were processed, scaled and 190 
reduced using XDS (16) and programs from the CCP4 suite (7). The crystal structures of the Fab 191 
complexes were determined by the molecular replacement method using Phaser (30). The 192 
molecular replacement for Fab HC33.4 was performed using separate variable and constant 193 
regions of a hypothetical Fab fragment assembled from the LC of PDB accession code 4JZO (89% 194 
aa identity) and the HC of PDB accession code 3KDM (91% aa identity) as search model. The 195 
molecular replacement for Fab HC33.8 was performed using Fab HC33.4 as search model. 196 
Model building was performed using Coot (11) and refinement was done using AutoBuster (3). 197 
Difference maps calculated after refinement of the Fab molecules revealed an unambiguous 198 
side chain density for a tryptophan residue close to the complementarity determining regions 199 
(CDRs), which allowed us to manually build a partial atomic model for the peptide comprising 200 
aa 418-421 (HC33.4 complex) and aa 415-421 (HC33.8), respectively. The atomic coordinates 201 
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and structure factors have been deposited in the Protein Data Bank, www.pdb.org, under the 202 
accession numbers 5FGB and 5FGC. 203 
Crystal structure analysis. Peptides were aligned using the MatchMaker algorithm 204 
implemented in Chimera (36) and an iterative alignment process pruning long atom pairs until 205 
no pair exceeds 1 Å. Root mean square deviations were calculated using Chimera. Buried 206 
solvent accessible surface areas for the interfaces as well as for individual residues within the 207 
peptides were calculated using the PISA server (27). Interactions were determined using the 208 
protein interactions calculator (PIC; (45)). Figures were prepared with PyMOL 209 
(http://www.pymol.org). 210 
Statistical analysis. Statistical tests were two-sided, and P values (calculated by Graphpad 211 
software) below 5% are considered significant.   212 
 213 
 214 
RESULTS  215 
HVR1 has different effects on blocking antibody access to epitopes on E2. HVR1 attenuates 216 
the activity of broadly neutralizing antibodies to HCV (1, 37). Its ability to decrease the potency 217 
of virus neutralizing antibodies was established with representative HMAbs to clusters of 218 
overlapping epitopes, designated as antigenic domains B and C (1). To test whether HVR1 acts 219 
by shielding access of these and other broadly neutralizing antibodies to their respective 220 
epitopes, binding studies were performed to 1a H77C recombinant E2 protein, with and 221 
without HVR1 (ΔHVR1) (Figs. 1A and 1B). Representative antigenic domain B antibodies (HC-1 222 
and HC-11 (19)) bound to higher levels to ΔHVR1 E2 than wt E2 but with different degrees of 223 
increase (86% and 14% , P <0.05). Antigenic domain D antibodies (HC84.20, HC84.24 and 224 
HC84.26 (24)) also bound more to ΔHVR1 E2 than to wt E2 (56-75%, P <0.05). CBH-7, an 225 
antigenic domain C antibody (13) also bound higher to ΔHVR1 E2 but with only a minimal 226 
increase (6%, P <0.05). 227 
We next interrogated HMAbs that recognize linear epitopes located in a highly conserved 228 
region on E2, encompassing aa 412-423, designated as antigenic domain E (17, 18), and 229 
observed two different patterns. HC33.1 behaved similarly to antigenic domain B and D 230 
antibodies with greater binding to ΔHVR1 E2 than wt E2 (50%, P < 0.001) (Figs. 1A and 1B). 231 
Unexpectedly, binding by three other E antibodies, HC33.4, HC33.8 and HC33.9, to ΔHVR1 E2 232 
was reduced compared to wt E2 protein (65-78%, P <0.05). The decrease in binding of these 233 
MAbs to ΔHVR1 E2 suggests that part of their epitopes may fall within the HVR1. 234 
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Epitope mapping of antibodies to a highly conserved region on E2. Prior mapping of HC33-235 
related HMAb epitopes was limited to aa 411-446 by alanine-scanning mutagenesis analysis of 236 
H77C E2 (17). That analysis revealed loss-of-binding residues located at L413, G418 and W420. 237 
We expanded on these results using alanine-scanning mutagenesis of aa 384-446 on E2, which 238 
included the entire HVR1 region (aa 384 to 410) (Fig. 1C).  The E2 mutants were expressed in 239 
293T cells and binding by HC33.1, HC33.4, HC33.8 and HC33.29 to cell lysates was measured by 240 
ELISA. Expression levels of the mutants were normalized by binding with CBH-17, a non-241 
neutralizing HMAb that recognizes a different linear epitope on HCV E2 (13). A test 242 
concentration of 50% maximum binding of each antibody was selected for epitope mapping 243 
studies. This was determined by dose-dependent binding of each HC33 HMAb to E2 that 244 
showed the test concentration in the linear portion of the binding curve (data not shown). A 245 
greater than 80% reduction in binding was observed again for all four HC33-related HMAbs with 246 
alanine substitutions at L413A, G418A and W420A (Fig. 1C), which suggests that they bind to 247 
the same or to nearly identical epitopes. Three of these antibodies, HC33.4, HC33.8 and 248 
HC33.29, also showed greater than 80% reduction in binding against a K408A mutant E2 249 
protein. Taken together, these mapping studies revealed two subsets of HC33-related 250 
antibodies, and explain why the deletion of HVR1 led to decreased binding by HC33.4, HC33.8 251 
and HC33.29, and not HC33.1.  252 
Anti-HVR1 antibody blocks the binding of broadly neutralizing antibodies. Epitope mapping of 253 
HC33-related antibodies revealed two subsets. One set, HC33.1, has contact residues that are 254 
restricted to aa 412-423. This is similar to other MAbs to this region, e.g. AP33, HCV1 and 255 
H77.39 (33, 38). The other set, HC33.4, HC33.8 and HC33.29, includes a putative contact 256 
residue within HVR1 that is located at aa 408. This raises the possibility that at least some anti-257 
HVR1 antibodies can interfere with the functions of antibodies to aa 412-423 because of their 258 
spatial proximity. To test this hypothesis, blocking studies were performed with two murine 259 
MAbs, H77.39 and H77.16 (38). H77.39 binds to an epitope centered at aa 412-423 whereas 260 
H77.16 recognizes an epitope within HVR1 (38). Epitope mapping by alanine scanning 261 
mutagenesis of H77C E2 from aa 384-446 confirmed that H77.39 recognizes residues (N415, 262 
G418 and W420) restricted to aa 412-423, whereas H77.16 binds to HVR1 residues (G406, K408 263 
and N410) (Fig. 1C). Each of these murine MAbs was tested for blocking of binding by 264 
representative antigenic domain B-E HMAbs (Fig. 2). H77C E2 was first incubated with either 265 
H77.39 or H77.16 prior to adding the test HMAb. As expected, H77.39 inhibited the binding to 266 
E2 of both subgroups of HC33 HMAbs (67-75%, P<0.05, (Fig. 2A). Inhibition also was observed 267 
against representative neutralizing HMAbs to two other epitope clusters. HC-1 and HC-11 268 
(antigenic domain B) were inhibited by H77.39 between 73-74% (P<0.05) and HC84.24 and 269 
HC84.26 (antigenic domain D) were inhibited between 64-69% (P <0.05). Against a neutralizing 270 
antibody (CBH-7) to a third domain C cluster, essentially no inhibition was observed (P>0.05). 271 
The inhibition of domain D HMAb binding by an antibody to aa 412-423 has been observed 272 
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previously and is unidirectional, which is consistent with proximity but not overlapping nature 273 
of their respective epitopes (17).   274 
Unexpectedly, H77.16, a murine MAb that binds primarily to 1a H77C HVR1 (38) also blocked 275 
both subsets of HC33-related HMAbs by 75-89% (P<0.05) (Fig. 2B). Although we anticipated 276 
inhibition by H77.16 against HC33.4, HC33.8 and HC33.9 because of the effect of the K408A 277 
mutation on their binding, we did not expect a loss of HC33.1 binding (Fig. 1C). H77.16 blocked 278 
antigenic domain B antibodies HC-1 and HC-11 by 51% to 53% (P<0.05) and antigenic domain D 279 
antibodies HC84.24 and HC84.26 by 39% to 44% (P<0.05). In contrast, binding by an antigenic 280 
domain C antibody, CBH-7 was not affected by H77.16 (P>0.05). Contact residues within HVR1 281 
have not been identified for antibodies to antigenic domains B, C and D in previous studies (13, 282 
19, 24). Thus, the global blocking effect of H77.16 on the binding of these broadly neutralizing 283 
antibodies suggests that anti-HVR1 antibodies may interfere with the neutralizing antibodies of 284 
antigenic domain B, D and E. 285 
Anti-HVR1 interferes with broadly neutralizing antibodies. We next examined the 286 
neutralization of 1a H77 HCVcc by representative antigenic domains B-E HMAbs in the presence 287 
or absence of “interfering” HMAbs. We assessed whether combinations of antibodies were 288 
antagonistic, additive or synergistic using the median-effect analysis method, as described in 289 
Materials and Methods (5). A constant ratio between the HVR1 antibody H77.16, and HC33.1 or 290 
HC33.4 (domain E), HC-11 (domain B), HC84.26 (domain E) or CBH-7 (domain C) was set by their 291 
respective IC50 concentrations against the 1a H77 (HJ3-5) HCVcc (48). The IC50 concentrations 292 
for HC-11 (1.2 µg/ml) and HC84.26 (0.080 µg/ml) were previously established (19, 24). Dose-293 
dependent neutralization was performed for H77.16, HC33.1, HC33.4 and CBH-7 that 294 
determined their respective IC50 values of 0.5, 3.24, 0.11 and 1.8 µg/ml (data not shown). Dose-295 
dependent neutralization was tested for each antibody and in combination in a range of two-296 
fold dilutions in concentration from 8(IC50) to 1/16(IC50). A representative set of analyses to 297 
determine cooperativity in virus neutralization is shown in Figures 3A-C for H77.16 and HC33.4. 298 
Dose-dependent neutralization for H77.16, HC33.4, and H77.16 + HC33.4 in combination from a 299 
dose of 8(IC50) to 1/32(IC50) was determined (Fig. 3A); fractional effect (FA) values were plotted 300 
in relation to dose (Fig. 3B); and combination index (CI) values were calculated and plotted in 301 
relation to fractional effect, FA (Fig. 3C). These studies were performed initially for H77.16 in 302 
combination with HC33.1, HC33.4, HC-11, HC84.26 or CBH-7. For each set of analyses, the linear 303 
correlation coefficient r was greater than 0.95 indicating a high goodness of fit to the plots 304 
(data not shown). The CI values of the paired studies at FA values of 50%, 75% and 90% 305 
effective dose (ED50, ED75 and ED90) were tabulated (Fig 3D). Aside from CBH-7, the CI values for 306 
the remaining antibodies, HC33.1, HC33.4, HC-11 or HC84.26, in combination with H77.16 at FA 307 
of ED50 (range: 1.44-1.84), ED75 (range: 1.31-2.76) and ED90 (range: 1.18-2.32) were all above 1, 308 
which indicates antagonism. Moderate (CI ranging between 1.2-1.45) antagonism was observed 309 
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between H77.16 and HC33.1 or HC84.26 (Fig. 4A). Stronger antagonism (ranging between 1.46-310 
3.0) was observed between H77.16 and HC33.4 or HC-11. These findings are consistent with the 311 
ability of H77.16 to interfere with the binding of representative antigenic domain B (HC-11), D 312 
(HC84.26) and E (HC33.1 and HC33.4) HMAbs. Additive cooperativity with CI values near 1.0 313 
(defined as 0.9-1.1) was observed between H77.16 and CBH-7, which is consistent with the 314 
minimal competition between these two antibodies (Figs.2B and 4A).  315 
To assess whether the mass of full-length IgG binding to HVR1 decreases access of broadly 316 
neutralizing antibodies to their epitopes on E2 by steric hindrance, combination antibody 317 
studies were repeated with H77.16 Fab2 fragments (Fig. 3D). As documented for each pair, the 318 
CI values at ED50, ED75, and ED90 were substantially lower for H77.16 Fab2 fragments than for 319 
intact H77.16 IgG in combination with HC33.1, HC33.4, HC-11 or HC84.26. The mean CI values 320 
for combination studies with H77.16 Fab2 ranged between 0.93-1.07 for H77.16 Fab2 molecules, 321 
which are within the additive range (Fig. 4B). The CI values for H77.16 Fab2 in combination with 322 
CBH-7 remained within the additive range (Fig. 3D and Fig. 4B). Because both H77.16 and 323 
HC33.4 have at least one critical residue within HVR1 by alanine substitution studies (Fig. 1C) 324 
and H77.16 Fab2 interferes less than full-length H77.16 against HC33.4 neutralization, inhibition 325 
of binding studies were performed. The findings showed that full-length H77.16 inhibited 326 
HC33.4 binding to E2 more than H77.16 Fab2 (P<0.05) (Fig. 4C). Thus, the mass of an intact IgG 327 
binding to an epitope in HVR1 decreases the access of broadly neutralizing antibodies to E2 to 328 
their respective epitopes. 329 
Temperature and time of addition alters anti-HVR1 interference of binding by broadly 330 
neutralizing antibodies. Previous studies with HCV (39) and other flaviviruses (9) demonstrated 331 
that higher incubation temperatures lead to greater antibody binding to cryptic epitopes 332 
because of enhanced viral protein motion. We hypothesized that at higher temperatures 333 
binding by broadly neutralizing antibodies would be increased due to greater exposure of their 334 
epitopes and decreased steric hindrance by anti-HVR1 MAbs. Two sets of H77C E2 were first 335 
exposed to H77.16 (20 µg/ml) at room temperature (RT). One (test) set was incubated at 400C 336 
incubator prior to adding antigenic domain E, B and D HMAbs; the other (control) set remained 337 
at RT prior to adding the HMAbs. After 30 minutes at either RT or 400 C, detection of test HMAb 338 
binding was determined by ELISA. Indeed, greater binding by each antigenic domain E, B and D 339 
HMAb was observed at 400C than at RT, and this was associated with significantly less inhibition 340 
by H77.16 at 400C than at RT (P <0.05, Fig. 5A). Furthermore, we tested whether pre-incubation 341 
with either broadly neutralizing antibodies or H77.16 affected the ability of H77.16 to interfere 342 
with the binding of E, B and D HMAbs. When E2 is first incubated with each E, B or D HMAb and 343 
followed by H77.16, virtually no inhibition of binding was observed by H77.16, as expected (Fig. 344 
5B). When E2 is first incubated by H77.16 and followed by each E, B or D HMAb, the 345 
magnitudes of inhibition by H77.16 against the domain E, B or E HMAbs were similar to the 346 
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observed inhibition, as shown in Figure 5A at RT. The control antibody, CBH-7, binding to E2 347 
was not affected by H77.16 under either test conditions (Fig. 5B). These observations support 348 
the hypothesis of steric hindrance of binding of broadly neutralizing MAbs by anti-HVR1 MAbs.   349 
Structure determination of Fab/peptide complexes. Because the HC33.4, HC33.8 and HC33.29 350 
epitopes appear to overlap between HVR1 and aa 412-423, structural analysis was performed. 351 
We expressed the Fab fragments derived from HC33.4 and HC33.8 and performed co-352 
crystallization trials of complexes containing the Fab and a peptide comprising residues 406-425 353 
(PGAKQNIQLINTNGSWHINST) of the genotype 1a strain H77. This peptide was chosen to include 354 
all putative contacts revealed by the alanine scanning mutagenesis, i.e., residues K408, L413, 355 
G418 and W420. We obtained crystals diffracting to 1.65Å resolution (Fab HC33.4) and 1.9Å 356 
resolution (Fab HC33.8), respectively (Table 1). The structures of both complexes were 357 
determined by the molecular replacement method (see Materials and Methods for more 358 
details). Since comparison of peptides from both complexes revealed an identical amino acid 359 
backbone conformation and the peptide in the HC33.8 complex structure is more complete, we 360 
concentrated our further analysis on this complex.  361 
Molecular determinants of Fab HC33.8 interaction with its peptide epitope. The conformation 362 
of the peptide in complex with Fab HC33.8 resembles the recently described conformation of a 363 
similar peptide in complex with Fab HC33.1 (29). The interaction between the peptide and Fab 364 
HC33.8 is dominated by the side chain of W420 that protrudes and is deeply immersed into a 365 
cavity formed by the long complementarity determining region 3 loop of the heavy chain (CDR-366 
H3), the framework residues around CDR-H2 and the CDR-L3 loop (Figs. 6B and C). This pattern 367 
agrees with the results of the alanine scanning mutagenesis with W420 being a primary 368 
determinant of antibody binding. The second residue that is suggested by the alanine scanning 369 
mutagenesis as crucial for an antibody/E2 interaction is G418. This glycine residue makes three 370 
hydrogen bonds involving main-chain atoms, however, this cannot explain the amino acid 371 
specificity suggested by alanine scanning mutagenesis. It is more likely that the extensive 372 
flexibility of the glycine residue is required to facilitate the protrusion of the W420 side chain 373 
into the described cavity in the paratope. In contrast to the HC33.1 complex, in which electron 374 
density was observed for residues 412-423, peptide residues 412-414 of the HC33.8 complex 375 
are likely to be disordered and no evidence for further direct interactions between antibody 376 
and peptide were observed.  377 
The peptide in the HC33.8 complex is exposed to the solvent and particularly N415 (i.e., the 378 
region directly downstream of the disordered part of the peptide) is located in a solvent 379 
channel (Fig. 6A), suggesting that crystal packing does not prevent a direct interaction between 380 
K408 and the antibody. However, the N-terminal peptide parts of the HC33.1 and HC33.8 381 
complexes likely differ due to a short stretch at the end of β-strand F in the heavy chain variable 382 
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region of HC33.8 (101VFTDS105 vs. 101VSSDI105 in HC33.1). The distances between superposed Cα-383 
atoms from the corresponding segments of HC33.1 and HC33.8 amount to 0.2Å and 0.6Å at 384 
residues 101 and 105, respectively, and to 4.3Å in the middle, with the HC33.8 segment bulging 385 
out. Fab HC33.1 tightly interacts with I414 in the N-terminal part of the peptide via two main 386 
chain hydrogen bonds from SH103, presumably stabilizing the peptide conformation in the 387 
HC33.1 complex. The bulge observed in the HC33.8 complex prohibits this interaction, 388 
suggesting major differences in the N-terminal part of the interface. The complex structure can 389 
therefore neither confirm nor rule out a direct interaction between antibody and the N-390 
terminal part of the peptide.  391 
Conformation of the E2 aa415-423 peptide in complex with Fab HC33.8. The peptide in the 392 
HC33.8 complex adopts an extended conformation similar to the conformation observed in 393 
complex with the related HC33.1 Fab (29). However, this binding mode contrasts with the β-394 
hairpin formed in complex with three independent neutralizing antibodies (26, 34) or with the 395 
extended conformation observed in complex with MAb 3/11 (31) (Fig. 7). All three backbone 396 
conformations have been observed in complex with broadly neutralizing antibodies underlining 397 
the structural flexibility at the surface of infectious virus particles. Our data suggest that 398 
different conformations of the antigenic region aa 412-423 are in equilibrium and that 399 
independent antibodies recognize this site following the principle of induced fit or 400 
conformational selection. The demonstrated conformational flexibility in this antigenic region 401 
supports the hypothesis of a temperature-dependent steric hindrance of binding of broadly 402 
neutralizing MAbs by anti-HVR1 MAbs. An intact IgG that dangles upstream of the flexible 403 
antigenic domain E, (i.e., one that binds the C-terminus of HVR1), sterically blocks binding of 404 
broadly neutralizing antibodies to adjacent epitopes. 405 
 406 
DISCUSSION 407 
The functional and biophysical properties of HVR1 on the E2 glycoprotein contribute to the 408 
ability of HCV to escape from immune recognition, which ultimately leads to persistent 409 
infection. The region is immunodominant and serves as a major decoy that diverts the B cell 410 
response from other more conserved regions on E2. Antibodies elicited to HVR1 are 411 
neutralizing but they are associated with rapid viral escape without compromising viral fitness. 412 
Prior studies have proposed that HVR1 structurally shields access by neutralizing antibodies to 413 
their respective epitopes (1). Our finding that broadly neutralizing HMAbs to overlapping 414 
conformational epitopes in E2 bind greater to ΔHVR1 E2 than wt E2 is consistent with this 415 
hypothesis.  416 
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The different binding patterns of a panel of HMAbs to mainly linear epitopes that are located 417 
adjacent to HVR1, encompassing aa 412-423 and designated as antigenic domain E, led to a 418 
series of studies that identified a new mechanism for HVR1 attenuation of antibody-mediated 419 
virus neutralization. We showed that when an anti-HVR1 antibody occupies its site on HVR1, 420 
access of antigenic domain E antibodies (e.g., HC33.1 and HC33.4) is compromised. Diminished 421 
access also was observed against antibodies to antigenic domains B (HC-1 and HC-11) and D 422 
(HC84.20, HC84.24 and HC84.26). The major binding regions for domains B and D have been 423 
mapped to aa 529-540 and aa 440-446, respectively (19, 24). The effect of anti-HVR1 on 424 
neutralization by antibodies recognizing antigenic domains B, D, and E antibodies was apparent 425 
in the antagonism studies by the median-effect analysis method. When the mass of the anti-426 
HVR1 antibody was reduced as Fab2 fragments, the observed antagonism anti-HVR1 was 427 
diminished. Furthermore, increased binding by each domains B, D and E HMAb was observed at 428 
400C than at RT, which is consistent with increased exposure of their cognate epitopes due to 429 
enhanced viral or in this case, protein ‘breathing’ at higher temperatures (9, 39). This led to 430 
decreased interference by anti-HVR1 antibodies. The drop in antagonism with H77.16 Fab2 431 
against both HC33.1 and HC33.4 appears similar, although the HC33.4 epitope includes a critical 432 
residue within HVR1 by alanine substitution studies. A possible explanation is that structural 433 
studies with both antibodies are nearly identical, which means that HC33.4 does not include a 434 
true contact residue at aa 408 (29). Taken together, these findings suggest that anti-HVR1 Abs 435 
interfere with the binding of broadly neutralizing antibodies by steric hindrance. Finally, the 436 
interference by H77.16 against domain E antibodies (HC33-related HMAbs) appears greater 437 
than H77.39, although H77.39 binds to the same region as antigenic domain E antibodies (Fig. 438 
2). The difference is probably due to the different mechanisms of interference. H77.39 directly 439 
competes for the same binding sites as the HC33-related antibodies that can be affected by the 440 
relative binding affinities of the two antibodies.  In contrast, H77.16 binds to an adjacent site in 441 
which the bulk of the antibody molecule is preventing the binding of HC33-related antibodies to 442 
their respective epitopes. The extent of blockade by steric hindrance is less dependent on 443 
differences in the affinities of the competing antibodies that could be more effective with the 444 
tested antibodies. The concept of antibody-mediated interference of HCV is not new. It has 445 
been proposed that epitopes within the E2 segment encompassing aa 434-446 elicit non-446 
neutralizing antibodies, and that these antibodies interfere with neutralizing antibodies 447 
directed at an adjacent E2 segment (aa 412-426) (49, 50). However, other studies employing 448 
similar approaches of isolating polyclonal antibodies to synthetic peptides encompassing aa 449 
412-426 and aa 434-446 showed no interference in virus neutralization (42). The lack of 450 
interference by antibodies to aa 434-446 was assessed by combination studies of HMAbs that 451 
bind to aa 412-426 or aa 434-446 (17, 24). The median-effect analysis method was applied and 452 
determined that the effect was additive and not antagonistic (17).   453 
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We performed structural studies to further understand how the binding of anti-HVR1 MAbs 454 
interferes with broadly neutralizing antibodies. The antigenic region aa 412-423 is positioned 455 
downstream of the HVR1, which is a structurally flexible region at the N-terminus of E2. HVR1 456 
was reported to interfere with binding of neutralizing antibodies by shielding conserved 457 
epitopes (1, 37). The different structures observed for peptides comprising aa 412-423 bound 458 
to multiple neutralizing antibodies suggests that this region also has considerable structural 459 
flexibility in the HCV particle. These observations indicate that there is a long, highly flexible 460 
region at the N-terminus of E2, which extends beyond HVR1 and includes conserved residues 461 
strongly implicated in CD81 binding. Since the majority of neutralizing epitopes within E2 is 462 
located in close proximity to this flexible region, MAbs targeting epitopes within this region 463 
likely can interfere- even in the absence of direct competition for binding residues- by steric 464 
hindrance, with binding of neutralizing antibodies to other antigenic domains within E2. 465 
Overall, our findings indicate that in addition to a direct shielding role of HVR1, an indirect 466 
shielding role is plausible and could be exerted by antibodies binding to the extended 467 
structurally flexible region at the N-terminus of E2 (including aa 412-423). Thus, immunization 468 
strategies that avoid the generation of HVR antibodies may be needed to enable broadly 469 
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FIGURE LEGENDS 625 
Figure 1: Binding properties of broadly neutralizing HMAbs.  (A) Antibody binding to wt or 626 
ΔHVR1 recombinant E2 by ELISA.  Recombinant H77C E2 cell lysate was captured by pre-coated 627 
GNA wells.  Bound proteins were incubated with each test HMAb at 1 µg/ml (x-axis) and bound 628 
antibody was detected by anti-human antibody. The y-axis shows the mean optical density 629 
values for triplicate wells, the mean of three experiments ±SD.  (B) Tabulation of difference in 630 
binding between ΔHVR1 and wt E2 with calculated P values. (C) Epitope mapping of HMAb 631 
(designated as HC33) and murine MAb (H77.39) to a highly conserved E2 region, aa 412-423, 632 
and a murine MAb to HVR1 (H77.16). E2 mutant proteins were expressed in 293T cells and cell 633 
lysates were analyzed by ELISA.  HC33.1, -.8 and -.29 were tested at 0.1 µg/ml and HC33.4 at 634 
0.05 µg/ml. The murine MAbs, H77.16 and H77.39 were tested at 0.1 µg/ml. Individual protein 635 
expression was normalized by binding of CBH-17, an HCV E2 HMAb to a linear epitope (13).  The 636 
E2 region encompassing aa 384-446 was analyzed. Red indicates 0-20%, orange 21-40%, brown 637 
41-60%, white 61-100% and green >100% binding when the residue was replaced by alanine (or 638 
glycine at aa 407), relative to binding to wt. Data are shown as mean values of two independent 639 
experiments performed in triplicate.   640 
Figure 2: Inhibition of binding by an antibody to HVR1 against broadly neutralizing HMAbs. (A 641 
and B) Competition studies with two murine MAbs against antigenic domain B-E HMAbs. 642 
Lysates of 293T cells expressing recombinant H77C E2 were used. Unlabeled murine MAb 643 
H77.39 (A) or H77.16 (B) at 20 µg/ml was first incubated with E2 that had been immobilized on 644 
an ELISA plate (24). Test HMAb at 1 µg/ml was then added and bound HMAb was measured as 645 
described (24).  The percent inhibition was based on test HMAb binding in the absence of the 646 
murine MAb. Data are shown as mean percent inhibition of two experiments performed in 647 
triplicate.   648 
Figure 3: Effects of combined MAbs to HVR1 and representative antigenic domain B-E in 649 
neutralizing 1a H77 HCVcc. (A) Dose-dependent neutralization of H77.16, HC33.4 and 650 
combined H77.16 plus HC33.4 at a constant ratio. Antibody concentrations were two-fold 651 
dilution from 8 times their respective (IC50) values to 1/32 of their respective (IC50) values. The 652 
constant ratio of the combined antibodies was their IC50 values. On the x-axis, a dose of 1 is at 653 
the IC50 concentration. Each assay was performed in four replicates and data are shown as 654 
percent neutralization, the mean ±SD. (B) The fractional effect (FA) plots generated by the 655 
CompuSyn program for H77.16, HC33.4 and their combination showing dosage vs. effect. (C) 656 
Median effect plot of calculated combination index (CI) values (logarithmic) vs. FA values, in 657 
which log CI<0 is synergism and >0 is antagonism. (D) Table of CI values for combinations of 658 
each H77.16 or H77.16 Fab2 with HC33.1, HC33.4, HC-11, HC84.26 or CBH-7 at FA values of 659 
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ED50, ED75 and ED90. Data are shown as mean percent inhibition of two experiments performed 660 
in triplicate.   661 
Figure 4: Cooperativity in functional effects of combined antibodies to HVR1 and HMAbs 662 
antigenic domains. Average CI values at FA of 0.5, 0.75 and 0.9 ± SD for virus neutralization 663 
with intact IgG (A) or Fab2 fragments (B) of H77.16 combined with HC33.1, HC33.4, HC-11, 664 
HC84.26 and CBH-7. Dotted lines indicate the range for antagonistic, additive or synergistic 665 
effects by their respective CI values. (C) Unlabeled full-length and Fab2 MAb H77.16 at 20 µg/ml 666 
were first incubated with E2 that had been immobilized on an ELISA plate (24). Test HC33.4 667 
HMAb at 1 µg/ml was then added and bound HMAb was measured as described (24). The 668 
percent inhibition was based on test HMAb binding in the absence of the murine MAb. Data are 669 
shown as mean percent inhibition of two experiments performed in triplicate.   670 
 671 
Figure 5: Inhibition of broadly neutralizing antibody binding is altered by changes in 672 
temperature of incubation and by timing of exposure. Cell lysates of 293T cell expressing 673 
recombinant H77C E2 were captured by pre-coated GNA wells in duplicate sets. (A) Unlabeled 674 
murine MAb H77.16 at 20 µg/ml was added to both sets of ELISA plates for 30 minutes at RT 675 
(24). One set was washed with buffer at RT and the other (test) set washed with buffer at 400C. 676 
The test set was placed in a 400C incubator for 10 minutes and the control set remained at RT. 677 
Each antigenic domain E (H33.1 and H33.4), B (HC-1 and HC-11) or D (HC84.24 and HC84.26) 678 
HMAb at 1 µg/ml was then added, and after 30 min at either RT or 400C, bound HMAb was 679 
measured at RT as described (24). The percent inhibition in either RT or 400C was based on each 680 
HMAb binding in the absence of the murine MAb. (B) H77.16 (labeled as H77.16 1st) or E, B or D 681 
HMAb (labeled as H77.16 2nd) was added to E2 for 30 minutes at RT. After washing, each E, B or 682 
D HMAb was added to E2 pre-incubated with H77.16 or H77.16 was added to E2 pre-incubated 683 
with E, B or D HMAbs for an additional 30 minutes. Control antibody was CBH-7, a domain C 684 
HMAb. Detection and calculation of percent inhibition were the same as (A). Data are shown as 685 
mean percent inhibition of two experiments performed in triplicate.   686 
Figure 6: Crystal structure of Fab HC33.8-peptide complex. The crystal structure of the Fab 687 
HC33.8-peptide complex was determined to 1.9 Å resolution. (A) View on the crystalline 688 
environment to determine crystal packing effects. The Fab is colored in light (light chain) and 689 
dark grey (heavy chain) and shown as molecular surface. The peptide (shown as a cartoon and 690 
ramp-colored from blue to red through yellow from N- to C- terminus) interacts mainly with the 691 
heavy chain and its N-terminus is exposed in a solvent channel (arrows). (B and C) View on the 692 
paratope of the Fab HC33.8-peptide complex from two angles illustrating the protruding side 693 
chain of W420 in a cavity formed by CDR 3 of the heavy chain 1, 2 and 3 (CDR-H3), CDR-L3 and 694 
framework residues surrounding the CDR-H2 loop. The Fab is colored as in A, CDRs 1, 2 and 3 695 
 21
are colored in cyan, light cyan and dark green for the heavy chain and in sand, olive and yellow 696 
for the light chain, respectively. The peptide is shown as a cartoon and colored by atom-type 697 
(orange, red and blue for carbon, oxygen and nitrogen, respectively) and binds to the paratope 698 
mostly between the long CDR-H3 loop (green) and the other heavy chain CDRs. A red ellipse 699 
highlights a short stretch at the end of β-strand F in the heavy chain variable region that bulges 700 
out in HC33.8, while it tightly interacts with the peptide in the HC33.1 complex (29). (D) View 701 
on the peptide (shown as molecular surface and colored as in B) rotated by 120° around the 702 
indicated axis with respect to panel C to illustrate how the W420 side chain protrudes from the 703 
bulge in the center of the peptide. 704 
Figure 7: Conformations of the antigenic region aa 412-423. Comparison of peptide 705 
conformations observed for aa 412-423. The peptides in complex with Fabs HC33.8 (A), 3/11 (B; 706 
PDB 4WHT) and HCV-1 (C; PDB 4DGV; (26) as an example for the β-hairpin conformation) are 707 
shown as cartoons with the side chains shown as sticks and colored by atom-type (red and blue 708 
for oxygen and nitrogen, respectively, and carbon atoms colored orange (HC33.8), grey (3/11) 709 
or green (HCV1)) to illustrate the differences in the backbone conformation observed for the 710 









Table 1. Data collection and refinement statistics. 
  Fab HC33-4 +   Fab HC33-8 +  
peptide peptide 
Data collection 
Space group P21 P2 
Complexes per AU 2 1 
Cell dimensions 
a, b, c (Å)  49.81 149.43 67.95  66.05 49.57 66.39 
a, b, γ (°)   90 90.08 90 90 98.5 90 
Resolution (Å)  47.25-1.65 (1.75-1.65)  49.57-1.90 (2.02-1.90) 
CC(1/2)   99.8 (68.8) 99.9 (89.8) 
I/ σI   12.52 (1.63) 16.17 (1.21) 
Completeness (%)   99.7 (98.4) 99.6 (97.8) 
Redundancy   5.3 (5.2) 6.6 (6.4) 
Refinement 
Resolution (Å)  24.16-1.65  49.57-1.90 
No. reflections   118727 33727 
Rwork/ Rfree  0.171 / 0.189  0.194 / 0.236 
No. of atoms 
Protein   6589 3414 
Ligand  - - 
Water   604 116 
Residues per AU   862 448 
B-factors 
Protein   20.8 38.1 
Ramachandran 
favored   98.00% 96.80% 
allowed  2.00% 2.70% 
outliers  0% 0.50% 
R.m.s. deviations 
Bond length (Å)   0.01 0.01 
Bond angles (°)  1.09 1.16 
1 Values in parentheses correspond to the highest resolution shell. 
rmsd, root-mean-square deviation. 
 
